10/576086 IAP15 R3C'd PCT/PTO 14 APR 2006

Docket No.: 0933-0273PUS1

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Ying ZHU et al.

Application No.: NEW

Confirmation No.: N/A

Filed: April 14, 2006

Art Unit: N/A

For:

TARGETING COMPOSITIONS AND

PREPARATION THEROF

Examiner: Not Yet Assigned

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith. US Patent Application Publication 2004/0213833-A1 corresponds to WO 02/076491-A1.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

10/576086

IAP15 Rec'd PCT/PTO 14 APR 2006

Application No.: NEW Docket No.: 0933-0273PUS1

A concise explanation of relevance of some of the items listed on form PTO/SB/08 is in

the form of an English language copy of a Search Report from a foreign patent office, issued in a

counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement

shall not be construed to mean that a search has been made or that no other material information

as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this

Information Disclosure statement shall not be construed to be an admission that any patent,

publication or other information referred to therein is "prior art" for this invention unless

specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR

1.98 and the Examiner is respectfully requested to consider the listed references.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future

replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for

any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of

time fees.

Dated: April 14, 2006

Respectfully submitted,

Gerald M. Murphy, Jr

Registration No. 28,977

BIRCH, STEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Road

Suite 100 East

P.O. Box 747

Falls Church, Virginia 22040-0747

(703) 205-8000

Attorney for Applicant

2 GMM/dns

## IAP15 Rec'd PCT/PTO 14 APR 2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

- Substitute for form 1449A/B/PTO			Complete if Known			
	Gussilate for form 1445/VS/1170			Application Number	NEW	10/576086
11	NFORMATION	SCLOSURE	Filing Date	April 14, 2	2006	
S	TATEMENT	APPLICANT	First Named Inventor	Ying ZHU		
			Art Unit	N/A		
	(Use as many sh	s necessary)	Examiner Name	Not Yet A	ssigned	
Sheet	1	of	1	Attorney Docket Number	0933-027	3PUS1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-2004/0213833-A1	10-28-2004	PENATE MEDINA et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	ВА	WO-02/076491-A1	10-03-2002			
	BB	WO-2004/029245-A1	04-08-2004			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
	CA	M. BJÖRKLUND et al., Use of Intein-Directed Peptide Biosynthesis to Improve Serum Stability and Bioactivity of a Gelatinase Inhibitory Peptide, Combinatorial Chemistry & High Throughput Screening, 2003, 29-35, 6.				
	СВ	S. DAGAR et al., VIP receptors as molecular targets of breast cancer: implications for targeted imaging and drug delivery, Journal of Controlled Release, 2001, 129-134, 74.				
	CC	B. KUHNAST et al., Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide, Nuclear Medicine and Biology, 2004, 337-344, 31.				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Com

Examiner	Date
Signature	Considered
Birch Stewart Kolasch & Birch LLP	GMM/dns

Birch, Stewart, Kolasch & Birch, LLP

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.